Navigation Links
Microbicide Developer Receives License for Novel HIV Microbicide Candidate From Merck & Co., Inc.
Date:3/11/2008

SILVER SPRING, Md., March 11 /PRNewswire-USNewswire/ -- In a boost to HIV prevention research, Merck & Co., Inc., has agreed to provide a royalty-free license to the non-profit International Partnership for Microbicides (IPM) to develop a novel antiretroviral compound for use as a potential vaginal microbicide.

The compound, called L'644, is a member of a class of antiretroviral molecules known as gp41 fusion inhibitors, which inhibit HIV infection by preventing the virus from fusing with the surface of target cells, an early step in the HIV infection process, potentially representing a novel way to block infection.

This announcement follows a similar agreement with Merck that granted IPM a royalty-free license in 2005 to develop another compound, L'167/CMPD167, which belongs to the class of molecules known as CCR5 blockers.

Microbicides are products, such as gels or films, that could be applied vaginally to prevent HIV transmission during vaginal intercourse. IPM is also developing other delivery methods, such as long-lasting vaginal rings that would release the drug gradually over time.

"Merck deserves recognition for its exemplary commitment to HIV prevention research," says Dr. Zeda Rosenberg, CEO of the International Partnership for Microbicides. "This arrangement for L'644 helps IPM pursue development of compounds that target HIV at many points in the virus's lifecycle. We're working toward the day when millions of women around the world will have access to safe and effective microbicides -- and partnerships like this will help us get there."

Preclinical research conducted by Merck suggests that L'644 is a potent HIV fusion inhibitor that is able to block infection of T cell targets in laboratory settings. For this reason there is a strong scientific rationale for evaluating its potential as an anti-HIV microbicide. Under the terms of the agreement, Merck grants IPM full royalty-free rights to develop L'644 a
'/>"/>

SOURCE International Partnership for Microbicides
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3

Related medicine technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
3. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
4. Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test
5. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
6. CryoCor Receives FDA Approval for Right Atrial Flutter
7. Ranbaxy Receives Approval to Manufacture and Market Hydrocodone Bitartrate and Acetaminophen Tablets USP
8. Dimericine(R) Receives FDA Fast Track Designation for Treatment Of Photosensitivity in XP Patients
9. Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
10. Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
11. The Female Health Company Receives USAID DELIVER PROJECT Order for 5 Million Units
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today ... Executive Officer of Neurocrine Biosciences, will be presenting at the ... in Boston.   The live presentation takes place ... 8:20 a.m. Pacific Time.  The presentation will be webcast and ... . If you are unable to attend ...
(Date:5/23/2013)... Hearing health affects a man,s lifestyle, and if ... and professionally engaged, he should address any hearing loss he ... Better Hearing Institute (BHI) is delivering to men ... Week , which leads up to and includes Father,s Day. ... through June 16. To help men address ...
(Date:5/23/2013)... 2013  Hadasit Bio-Holdings Ltd. (TASE: HDST, OTC: ... based on intellectual property developed and owned by ... foremost medical research center, today announced that its ... funding from the Israeli Ministry of Industry and ... support product development and advance clinical trials. Cell ...
Breaking Medicine Technology:Men Who Want to Stay Active, Feel Younger, and Remain Socially and Professionally Engaged Should Address Hearing Loss, BHI Advises 2Men Who Want to Stay Active, Feel Younger, and Remain Socially and Professionally Engaged Should Address Hearing Loss, BHI Advises 3Men Who Want to Stay Active, Feel Younger, and Remain Socially and Professionally Engaged Should Address Hearing Loss, BHI Advises 4Hadasit Bio-Holdings Ltd. Portfolio Company - Cell Cure Neurosciences Ltd. Received Additional Government Support 2
... Mich., Aug. 6 Terumo Heart, Inc. announced,that ... Ventricular Assist,System (LVAS) took place on July 30 ... Arbor, Michigan. The surgery was performed by,Francis Pagani, ... Pivotal Trial. DuraHeart is the world,s first third,generation ...
... Nexgen Spine, a leading,developer of innovative spinal implants ... today that it has received CE mark,approval to ... European,Union., "We are delighted that the Physio-L(R) ... Alastair Clemow, Ph.D., President and CEO,of Nexgen Spine. ...
Cached Medicine Technology:First DuraHeart(TM) Left Ventricular Assist System Implanted in the U.S. Pivotal Trial 2Nexgen Spine Receives CE Mark Approval for the Physio-L(R) Artificial Disc 2
(Date:5/23/2013)... Science published an article about bexarotene as ... important starting point for further Alzheimer,s research. The research ... VIB and KU Leuven in collaboration with the ... scientists at Janssen Pharmaceutica, Beerse, also tested this candidate ... were different, as were those of two American study ...
(Date:5/23/2013)... while being dragged to its destruction inside a ... sending signals that thwart the development of tumor-suppressing ... an early online publication at Nature . ... by tumors, the epidermal growth factor receptor (EGFR) ... team led by scientists at The University of ...
(Date:5/23/2013)... May 23, 2013 The Rottenstein Law ... firm, has created the Tylenol Lawsuit Information Center at ... Tylenol users and those who are considering filing lawsuits. ... to potentially cause severe liver damage, according to a ... In the “safety communication,” the FDA warned consumers ...
(Date:5/23/2013)... Washington, DC (PRWEB) May 23, 2013 ... have a great deal of control over their level ... their weight, yet far fewer are actually taking that ... International Food Information Council (IFIC) Foundation’s 2013 Food & ... of respondents say it’s possible to have “a great ...
(Date:5/23/2013)... IL (PRWEB) May 23, 2013 Jeanne ... fifth anniversary of its popular and only free OCD ... a successful continuing resource for OCD sufferers, the group ... OCD, and related disorders. This allows group participants ... and Exposure and Response Prevention. , “Participants in Beyond ...
Breaking Medicine News(10 mins):Health News:New insights contradict promising Alzheimer's research 2Health News:When oxygen is short, EGFR prevents maturation of cancer-fighting miRNAs 2Health News:When oxygen is short, EGFR prevents maturation of cancer-fighting miRNAs 3Health News:Rottenstein Law Group LLP Now Accepting Tylenol Cases, Announces New Tylenol Lawsuit Information Center 2Health News:Americans Experience “Control Gap” Regarding Their Weight, Diet, Activity Level; Rate Their Overall Diet a “B-Minus” 2Health News:Americans Experience “Control Gap” Regarding Their Weight, Diet, Activity Level; Rate Their Overall Diet a “B-Minus” 3Health News:Americans Experience “Control Gap” Regarding Their Weight, Diet, Activity Level; Rate Their Overall Diet a “B-Minus” 4Health News:Beyond OCD Support Group Marks Fifth Anniversary 2
... WASHINGTON Say nanotechnology, and geeks imagine iPhones, laptops ... of the 580 products in a newly updated ... items as tennis racquets, clothing, and health products. ... Nanotechnologies at www.nanotechproject.org/consumerproducts, the updated inventory includes Head ...
... Oct. 2 On Saturday, September 29, over 850,people ... of the most,grueling workouts ever devised, the Crossfit Fight ... Cure, an initiative of the Prostate Cancer,Foundation. Over 4,000 ... pledges and thanks to a matching funds grant from ...
... Ranbaxy One of Few Companies to Offer Both Suspension ... Ranbaxy Pharmaceuticals Inc.,(RPI), a wholly owned subsidiary of Ranbaxy ... approval from the U.S. Food and,Drug Administration (U.S. FDA) ... mg/5 mL and 250 mg/5 mL. Ranbaxy is the ...
... CYNACON/OCuSOFT (OCuSOFT,Inc.), a company specializing in ... optometrists, is pleased to announce the,appointment of ... Scientific,Advisory Board. *(LOGO: Send2Press.com/mediaboom/07-0803-Occusoft_72dpi.jpg) Dr. ... Eye Surgery in New York,City. She is ...
... producers,in the United States should be cautious but not ... director at Kansas,State University. Gary Anderson, director of ... the virus, which recently cropped up in the United,Kingdom, ... United States. "We are fortunate that bluetongue virus ...
... SAN FRANCISCO, Oct. 2 The American Dental,Association ... the,disposal of dental amalgam waste to include the ... plumbing to capture and,remove at least 95 percent ... system. The use of separators will allow greater ...
Cached Medicine News:Health News:Nanotechnology: not just for geeks 2Health News:Crossfit Workout Challenge Raises Over $500,000 in Four Hours for Athletes for a Cure 2Health News:Ranbaxy First to Gain Approval to Manufacture and Market Clarithromycin for Oral Suspension, USP 2Health News:K-State Veterinary Lab Routinely Tests For Bluetongue Virus; Lab Director Says Strains Found in Kansas, U.S. Usually Less-Virulent 2Health News:ADA Updates Environmental Recommendations for Handling Waste 2
... any arm -- simply bend the aluminum forearm ... The cuffs are connected by an aluminum bar ... elbow angle. The central part of the joiner ... elbow joint.,Special attention is paid to the patient ...
... lightweight ankle splint may be used for ... ankle. It is effective in stabilizing ... or after cast removal. The rigid ... excellent side-to-side support. The stays also ...
... is designed to assist ambulation for those ... resulting in drop-foot. The anatomically correct shape ... is fabricated from specially formed orthopedic grade ... and reliability. For a more comfortable individual ...
... The VacoSplint has a rigid shell with ... an immobilized foot/ankle. The VacoSplint is a non-weight ... weight bear he/she should transfer to the STORM ... remove the nylon liner from the STORM and ...
Medicine Products: